# NIH Reporter #1R01AI201701-01

Immunomodulatory Blockade of Type 2 Immunity for Severe Coccidioidomycosis

**Recipient:** University of California Los Angeles (UCLA)

**Award Amount:** $787,484.00
**Ceiling:** $787,484.00

**Awarded:** August 11, 2026

**Identifier:** 1R01AI201701-01

The project will evaluate dupilumab as an add-on treatment for severe Valley fever and assess its effects on immune responses and clinical outcomes.

### Description

A prospective, randomized, placebo-controlled, blinded trial testing whether adjunctive dupilumab with standard antifungal medicines improves outcomes for patients with severe coccidioidomycosis and Type 2 immune skewing.

[View original record](https://reporter.nih.gov/search/Z6-pLStXck6naeyMsC9RTw/project-details/11435100)
